jak inhibitor

- News
Pandemic poses opportunity to online learning platform OpenLearning
Public
- News
Novatti partners with Ripple for global blockchain payments network
Public
- Opinion
Is ASX: OOO the riskiest or smartest oil investment?
Public
- Opinion
What the SportsBet-BetEasy merger means for TabCorp and punters
Public

Crowd Media adds voice cloning for immersive celebrity experiences in AI deal
- Review
- January 27, 2021
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Novatti to drive Malaysia into the digital payments era with ATX acquisition
- Review
- October 20, 2021
Apiam expands equine vet footprint in Queensland in time for breeding season
- Review
- June 30, 2021
Retired NFL players endorse Zilosul, Paradigm’s osteoarthritis drug trials
- Review
- March 24, 2020

Fibrosis is the simple disease process that’s more important than you think
- News
Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
- News
The Cancer Index: Why investing in oncology biotechs is more science than art
- News
“Scars are more than skin deep”: Why Professor Fiona Wood is working with this biotech to melt away scars
- News
Wellfully set to jump into $9 billion market with FDA registration for their knee pain patch
- News

- News
International expansion as more hospitals register for Pharmaxis’ cancer treatment trials
Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug, PXS-5505. The Company has launched new clinical trial sites in Taiwan in a planned expansion to boost patient recruitment. Designed for use in the treatment of myelofibrosis, a rare blood cancer with a poor prognosis,
Read More
Public